Hostname: page-component-669899f699-cf6xr Total loading time: 0 Render date: 2025-04-25T10:57:18.372Z Has data issue: false hasContentIssue false
  • English
  • Français

Use of cannabis in the treatment of animals: a systematic review of randomized clinical trials

Published online by Cambridge University Press:  15 June 2022

Tácio de Mendonça Lima Open the ORCID record for Tácio de Mendonça Lima [Opens in a new window] ,
Nathania Rodrigues Santiago ,
Elaine Cristina Ramos Alves ,
Douglas Siqueira de Almeida Chaves Open the ORCID record for Douglas Siqueira de Almeida Chaves [Opens in a new window]  and
Marília Berlofa Visacri Open the ORCID record for Marília Berlofa Visacri [Opens in a new window]
Tácio de Mendonça Lima*
Affiliation:
Department of Pharmaceutical Sciences, Federal Rural University of Rio de Janeiro, Seropédica, RJ 23897-000, Brazil
Nathania Rodrigues Santiago
Affiliation:
School of Veterinary and Zootechny, Federal University of Goias, Goiania, GO 74690-900, Brazil
Elaine Cristina Ramos Alves
Affiliation:
Centro Infantil Boldrini, Campinas, SP 13083-210, Brazil
Douglas Siqueira de Almeida Chaves
Affiliation:
Department of Pharmaceutical Sciences, Federal Rural University of Rio de Janeiro, Seropédica, RJ 23897-000, Brazil
Marília Berlofa Visacri
Affiliation:
Department of Pharmacology, School of Medical Sciences, University of Campinas, Campinas, SP 13083-887, Brazil
*
Author for correspondence: Tácio de Mendonça Lima, E-mail: [email protected]; [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Cannabis is used in the treatment of several human conditions; however, its use is still less explored in veterinary medicine. This systematic review aims to summarize the evidence of efficacy and safety of the use of cannabis for the treatment of animal disease. A literature search was performed for studies published until 16 March 2021 in five databases. Randomized clinical trials (RCTs) that reported the efficacy or safety of cannabis in the treatment of animal disease were included. The RoB 2 Tool was used to assess the risk of bias. A total of 2427 records were identified, of which six studies fully met the eligibility criteria. RCTs were conducted in dogs with osteoarthritis (n = 4), with epilepsy (n = 1), and with behavioral disorders (n = 1). All studies used cannabidiol (CBD) oil in monotherapy or in combination with other drugs. Studies used CBD at 2 or 2.5 mg kg−1 twice daily (n = 4), orally (n = 5), during 4 or 6 weeks (n = 3), and compared CBD with placebo (n = 5). CBD significantly reduced pain and increased activity in dogs with osteoarthritis (n = 3). Moreover, CBD significantly reduced the frequency of seizures in dogs with epilepsy (n = 1) and the aggressive behavior of dogs (n = 1). Although promising results were identified, studies were heterogeneous and presented risks of bias that required caution in the interpretation of findings. Therefore, there was some evidence to support the use of CBD in dogs with osteoarthritis to reduce pain and increased activity, but limited evidence against epilepsy and behavioral problems. In addition, CBD was well tolerated with mild adverse effects. More RCTs with high quality of evidence are needed, including greater numbers of animal subjects, additional species, and clear readout measures to confirm these findings.

Keywords

Animalcannabispetsystematic reviewveterinary medicine
Type
Systematic Review
Information
Animal Health Research Reviews , Volume 23 , Issue 1 , June 2022 , pp. 25 - 38
Check for updates
Copyright
Copyright © The Author(s), 2022. Published by Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Bornheim, LM and Correia, MA (1989) Effect of cannabidiol on cytochrome P-450 isozymes. Biochemical Pharmacology 38, 2789–2794.CrossRefGoogle ScholarPubMed
Brioschi, FA, Di Cesare, F, Gioeni, D, Rabbogliatti, V, Ferrari, F, D'Urso, ES, Amari, M and Ravasio, G (2020) Oral transmucosal cannabidiol oil formulation as part of a multimodal analgesic regimen: effects on pain relief and quality of life improvement in dogs affected by spontaneous osteoarthritis. Animals (Basel) 10, 1505.CrossRefGoogle ScholarPubMed
Campos, AC, Ferreira, FR and Guimarães, FS (2012) Cannabidiol blocks long-lasting behavioral consequences of predator threat stress: possible involvement of 5HT1A receptors. Journal of Psychiatric Research 46, 1501–1510.CrossRefGoogle ScholarPubMed
Carrier, EJ, Auchampach, JA and Hillard, CJ (2006) Inhibition of an equilibrative nucleoside transporter by cannabidiol: a mechanism of cannabinoid immunosuppression. Proceedings of the National Academy of Sciences of the USA 103, 7895–7900.CrossRefGoogle ScholarPubMed
Charalambous, M, Brodbelt, D and Volk, HA (2014) Treatment in canine epilepsy – a systematic review. BMC Veterinary Research 10, 257.CrossRefGoogle ScholarPubMed
Cimino Brown, D (2017) What can we learn from osteoarthritis pain in companion animals? Clinical and Experimental Rheumatology 35, 53–58.Google ScholarPubMed
Citti, C, Linciano, P, Russo, F, Luongo, L, Lannotta, M, Maione, S, Laganà, A, Capriotti, AL, Vandelli, MA, Gigli, G and Cannazza, G (2019) A novel phytocannabinoid isolated from Cannabis sativa L. with an in vivo cannabimimetic activity higher than Δ9-tetrahydrocannabinol: Δ9-Tetrahydrocannabiphorol. Scientific Reports 9, 20335.CrossRefGoogle Scholar
Corsetti, S, Borruso, S, Malandrucco, L, Spallucci, V, Maragliano, L, Perino, R, D'Agostino, P and Natoli, E (2021) Cannabis sativa L. may reduce aggressive behaviour towards humans in shelter dogs. Scientific Reports 11, 2773.CrossRefGoogle ScholarPubMed
Deabold, KA, Schwark, WS, Wolf, L and Wakshlag, JJ (2019) Single-dose pharmacokinetics and preliminary safety assessment with use of CBD-rich hemp nutraceutical in healthy dogs and cats. Animals (Basel) 9, 832.CrossRefGoogle ScholarPubMed
De Briyne, N, Holmes, D, Sandler, I, Stiles, E, Szymanski, D, Moody, S, Neumann, S and Anadón, A (2021) Cannabis, cannabidiol oils and tetrahydrocannabinol – what do veterinarians need to know? Animals (Basel) 11, 892–911.CrossRefGoogle ScholarPubMed
De Petrocellis, L, Ligresti, A, Moriello, AS, Allarà, M, Bisogno, T, Petrosino, S, Stott, CG and Di Marzo, V (2011) Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. British Journal of Pharmacology 163, 1479–1494.CrossRefGoogle ScholarPubMed
FDA (2021) FDA regulation of cannabis and cannabis-derived products, including cannabidiol (CBD). FDA. [Viewed 15 August 2021]. Available at https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd.Google Scholar
Fisher, E, Moore, RA, Fogarty, AE, Finn, DP, Finnerup, NB, Gilron, I, Haroutounian, S, Krane, E, Rice, ASC, Rowbotham, M, Wallace, M and Eccleston, C (2021) Cannabinoids, cannabis, and cannabis-based medicine for pain management: a systematic review of randomised controlled trials. Pain 162, S45–S66.Google ScholarPubMed
Gamble, LJ, Boesch, JM, Frye, CW, Schwark, WS, Mann, S, Wolfe, L, Brown, H, Berthelsen, ES and Wakshlag, JJ (2018) Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs. Frontiers in Veterinary Science 5, 165.CrossRefGoogle ScholarPubMed
Greb, A and Puschner, B (2018) Cannabinoid treats as adjunctive therapy for pets: gaps in our knowledge. Toxicology Communications 2, 10–14.CrossRefGoogle Scholar
Hall, W, Stjepanović, D, Caulkins, J, Lynskey, M, Leung, J, Campbell, G and Degenhardt, L (2019) Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. Lancet (London, England) 26, 1580–1590.Google Scholar
Hartsel, JA, Boyar, K, Pham, A, Silver, RJ and Makriyannis, A (2019) Cannabis in veterinary medicine: Cannabinoid therapies for animals. In Gupta, RC, Srivastava, A and Lall, R (eds), Nutraceuticals in Veterinary Medicine. Cham, Switzerland: Springer International Publishing, pp. 121–155.CrossRefGoogle Scholar
Kogan, L, Schoenfeld-Tacher, R, Hellyer, P and Rishniw, M (2019) US veterinarians’ knowledge, experience, and perception regarding the use of cannabidiol for canine medical conditions. Frontiers in Veterinary Science 5, 338.CrossRefGoogle ScholarPubMed
Landa, L, Sulcova, A and Gbelec, P (2016) The use of cannabinoids in animals and therapeutic implications for veterinary medicine: a review. Veterinarni Medicina 61, 111–122.CrossRefGoogle Scholar
Landis, SC, Amara, SG, Asadullah, K, Austin, CP, Blumenstein, R, Bradley, EW, Crystal, RG, Darnell, RB, Ferrante, RJ, Fillit, H, Finkelstein, R, Fisher, M, Gendelman, HE, Golub, RM, Goudreau, JL, Gross, RA, Gubitz, AK, Hesterlee, SE, Howells, DW, Huguenard, J, Kelner, K, Koroshetz, W, Krainc, D, Lazic, SE, Levine, MS, Macleod, MR, McCall, JM, Moxley, RT 3rd, Narasimhan, K, Noble, LJ, Perrin, S, Porter, JD, Steward, O, Unger, E, Utz, U and Silberberg, SD (2012) A call for transparent reporting to optimize the predictive value of preclinical research. Nature 490, 187–191.Google Scholar
Lundh, A, Lexchin, J, Mintzes, B, Schroll, JB and Bero, L (2017) Industry sponsorship and research outcome. Cochrane Database of Systematic Reviews 2, MR000033.Google ScholarPubMed
McGrath, S, Bartner, LR, Rao, S, Packer, RA and Gustafson, DL (2019) Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. Journal of the American Veterinary Medical Association 254, 1301–1308.CrossRefGoogle ScholarPubMed
McKee, KA, Hmidan, A, Crocker, CE, Lam, RW, Meyer, JH, Crockford, D, Trépanier, A, Aitchison, KJ and Tibbo, PG (2021) Potential therapeutic benefits of cannabinoid products in adult psychiatric disorders: a systematic review and meta-analysis of randomised controlled trials. Journal of Psychiatric Research 140, 267–281.CrossRefGoogle ScholarPubMed
Mejia, S, Duerr, FM, Griffenhagen, G and McGrath, S (2021) Evaluation of the effect of cannabidiol on naturally occurring osteoarthritis-associated pain: a pilot study in dogs. Journal of the American Animal Hospital Association 57, 81–90.CrossRefGoogle ScholarPubMed
Mücke, M, Phillips, T, Radbruch, L, Petzke, F and Häuser, W (2018) Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database of Systematic Reviews 3, CD012182.Google ScholarPubMed
Ouzzani, M, Hammady, H, Fedorowicz, Z and Elmagarmid, A (2016) Rayyan-a web and mobile app for systematic reviews. Systematic Reviews 5, 210.CrossRefGoogle ScholarPubMed
Page, MJ, McKenzie, JE, Bossuyt, PM, Boutron, I, Hoffmann, TC, Mulrow, CD, Shamseer, L, Tetzlaff, JM, Akl, EA, Brennan, SE, Chou, R, Glanville, J, Grimshaw, JM, Hróbjartsson, A, Lalu, MM, Li, T, Loder, EW, Mayo-Wilson, E, McDonald, S, McGuinness, LA, Stewart, LA, Thomas, J, Tricco, AC, Welch, VA, Whiting, P and Moher, D (2021) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Research ed.) 372, n71.Google ScholarPubMed
Pavlovic, R, Nenna, G, Calvi, L, Panseri, S, Borgonovo, G, Giupponi, L, Cannazza, G and Giorgi, A (2018) Quality traits of “cannabidiol oils”: cannabinoids content, terpene fingerprint and oxidation stability of European commercially available preparations. Molecules (Basel, Switzerland) 23, 1230.CrossRefGoogle ScholarPubMed
Pratt, M, Stevens, A, Thuku, M, Butler, C, Skidmore, B, Wieland, LS, Clemons, M, Kanji, S and Hutton, B (2019) Benefits and harms of medical cannabis: a scoping review of systematic reviews. Systematic Reviews 8, 320.Google ScholarPubMed
Repetti, CSF, Girio, RJS, Friolani, M and Barbalho, SM (2019) Perspectives in veterinary medicine on the use of cannabinoids as complementary palliative therapy for pain in cancer patients. Ciência Rural 49, e20180595.CrossRefGoogle Scholar
Ritter, S, Zadik-Weiss, L, Almogi-Hazan, O and Or, R (2020) Cannabis, one health, and veterinary medicine: cannabinoids’ role in public health, food safety, and translational medicine. Rambam Maimonides Medical Journal 11, e0006.CrossRefGoogle ScholarPubMed
Rufiange, M, Rousseau-Blass, F and Pang, DSJ (2019) Incomplete reporting of experimental studies and items associated with risk of bias in veterinary research. Veterinary Record Open 6, e000322.CrossRefGoogle ScholarPubMed
Sargeant, JM and O'Connor, AM (2020) Scoping reviews, systematic reviews, and meta-analysis: applications in veterinary medicine. Frontiers in Veterinary Science 7, 11.CrossRefGoogle Scholar
Sechi, S, Di Cerbo, A, Canello, S, Guidetti, G, Chiavolelli, F, Fiore, F and Cocco, R (2017) Effects in dogs with behavioural disorders of a commercial nutraceutical diet on stress and neuroendocrine parameters. The Veterinary Record 180, 18.Google ScholarPubMed
Sterne, JAC, Savović, J, Page, MJ, Elbers, RG, Blencowe, NS, Boutron, I, Cates, CJ, Cheng, HY, Corbett, MS, Eldridge, SM, Emberson, JR, Hernán, MA, Hopewell, S, Hróbjartsson, A, Junqueira, DR, Jüni, P, Kirkham, JJ, Lasserson, T, Li, T, McAleenan, A, Reeves, BC, Shepperd, S, Shrier, I, Stewart, LA, Tilling, K, White, IR, Whiting, PF and Higgins, JPT (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ (Clinical Research ed.) 366, l4898.Google ScholarPubMed
Sylantyev, S, Jensen, TP, Ross, RA and Rusakov, DA (2013) Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proceedings of the National Academy of Sciences of the USA 110, 5193–5198.CrossRefGoogle ScholarPubMed
Thomas, BF and ElSohly, MA (2016) The botany of Cannabis sativa L. In Thomas BF and ElSohly MA (eds), The Analytical Chemistry of Cannabis: Quality Assessment, Assurance, and Regulation of Medicinal Marijuana and Cannabinoid Preparations. Amsterdam, Netherlands: Elsevier, pp. 1–26.Google Scholar
Verrico, CD, Wesson, S, Konduri, V, Hofferek, CJ, Vazquez-Perez, J, Blair, E, Dunner, K Jr, Salimpour, P, Decker, WK and Halpert, MM (2020) A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain. Pain 161, 2191–2202.CrossRefGoogle ScholarPubMed
Virga, V, Houpt, KA and Scarlett, JM (2001) Efficacy of amitriptyline as a pharmacological adjunct to behavioral modification in the management of aggressive behaviors in dogs. Journal of the American Animal Hospital Association 37, 325–330.CrossRefGoogle ScholarPubMed
Wareham, KJ, Hyde, RM, Grindlay, D, Brennan, ML and Dean, RS (2017) Sponsorship bias and quality of randomised controlled trials in veterinary medicine. BMC Veterinary Research 13, 234.CrossRefGoogle ScholarPubMed
Supplementary material: File

Lima et al. supplementary material

Lima et al. supplementary material

Download Lima et al. supplementary material(File)
File 17.9 KB